Compared with conventional CD47 antibodies, the use of Lemzoparlimab effectively targets tumor cells while minimizing the adverse erythrocyte effects, thereby avoiding severe anemia (Junyuan et al., 2020). The gene discussed is CD47; the disease is neoplasm.